Immunotherapy with Vitamin D and Phenylbutyrate Explored for HIV Immune Reconstitution

HIV infection leads to progressive immune system damage and chronic inflammation, significantly impacting patient health. While current antiretroviral therapy (ART) effectively suppresses viral load, it often fails to fully restore immune function or resolve persistent inflammation. This study aimed to investigate if adjunctive immunotherapy with vitamin D and phenylbutyrate could enhance antimicrobial defenses and reduce inflammation in treatment-naive HIV patients.

The provided abstract for NCT01702974 does not detail specific results or outcome data from the completed trial, thus actual efficacy and safety profiles cannot be reported here. However, based on the study's stated aim, a successful outcome would have demonstrated that the combination of vitamin D and PBA significantly enhanced antimicrobial defense mechanisms in HIV-infected patients. This could manifest as a reduction in specific inflammatory biomarkers (e.g., C-reactive protein, IL-6) by a notable percentage, potentially in the range of 20-30%, compared to the placebo group. A key finding would be a measurable improvement in immune reconstitution, such as an increase in CD4+ T-cell counts by at least 50 cells/µL or a decrease in viral reservoir size, indicating a more robust immune response beyond what standard ART alone achieves. Such results would suggest that adjunctive therapy could contribute to better long-term outcomes for HIV-infected patients by mitigating chronic inflammation and bolstering host defenses.